ReviewCurrent opinion in genetics & development2017
Genetic susceptibility to neuroblastoma.
Review in Current opinion in genetics & development, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Pooled it
- Association between PHOX2B gene rs28647582 T>C polymorphism and Wilms tumor susceptibility.Bioscience reports · 2019Trial
- Peripheral neuroblastic tumors: tumor biology and its implications for risk stratification.European journal of pediatrics · 2025Review
- Association between MYCN gene polymorphisms and neuroblastoma susceptibility: a case-control study in Chinese children from Jiangsu Province.BMC cancer · 2025Article
- The relative contributions of genetic and non-genetic factors to the risk of neuroblastoma.Pediatric investigation · 2025Review
- Article
- ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Neural crest-related NXPH1/α-NRXN signaling opposes neuroblastoma malignancy by inhibiting organotropic metastasis.Oncogene · 2023Article
- Identification of Mitochondrial DNA Variants Associated With Risk of Neuroblastoma.Journal of the National Cancer Institute · 2022Article
- Genetic Analysis in African American Children Supports Ancestry-Specific Neuroblastoma Susceptibility.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Temporal clustering of neuroblastic tumours in children and young adults from Ontario, Canada.Environmental health : a global access science source · 2022Article
- Review
- Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?International journal of molecular sciences · 2021Review
- Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsedCold Spring Harbor molecular case studies · 2021Article
- A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma.Journal of experimental & clinical cancer research : CR · 2021Review
- Associations betweenTranslational pediatrics · 2021Article
- Article
- A Survey of Compound Heterozygous Variants in Pediatric Cancers and Structural Birth Defects.Frontiers in genetics · 2021Article
- Association of high-risk neuroblastoma classification based on expression profiles with differentiation and metabolism.PloS one · 2021Article
- Mitochondrial DNA Haplogroups and Susceptibility to Neuroblastoma.Journal of the National Cancer Institute · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Until recently, the genetic basis of neuroblastoma, a heterogeneous neoplasm arising from the developing sympathetic nervous system, remained undefined. The discovery of gain-of-function mutations in the ALK receptor tyrosine kinase gene as the major cause of familial neuroblastoma led to the discovery of identical somatic mutations and rapid advancement of ALK as a tractable therapeutic target. Inactivating mutations in a master regulator of neural crest development, PHOX2B, have also been identified in a subset of familial neuroblastomas. Other high penetrance susceptibility alleles likely exist, but together these heritable mutations account for less than 10% of neuroblastoma cases. A genome-wide association study of a large neuroblastoma cohort identified common and rare polymorphisms highly associated with the disease. Ongoing resequencing efforts aim to further define the genetic landscape of neuroblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.